clinical trial · NCT07137598
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Hoffmann-La Roche·phase2·recruiting·n = 160
Rheumatoid ArthritisAfimkibartPlacebo
brief summary
This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.
started
Dec 5, 2025
primary completion
Apr 17, 2027
completion
Oct 2, 2027
last updated
Apr 3, 2026
official title
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol